Findpharma.com has reported that clinical trial dropouts are at unsustainable levels.
Phase III trial terminations doubled from 2008-2010 compared to 2005-2007 and research and development spending was at it’s lowest for three years in 2010. The number of drugs entering Phase III trials dropped by over 50% in 2010. Phase I and II trial successes also fell by around 50% in the same year.
The increase in trial dropouts has been blamed on research and development cutbacks, with over $2 billion less spent across the whole pharmaceutical market. Reduced research and development spending is reflective of the lack of profit from pharmaceutical R&D.
Looking for a job in the pharmaceutical industry? Start looking here, now